<DOC>
	<DOCNO>NCT00573638</DOCNO>
	<brief_summary>The study hypothesis Xal-Ease increase patient compliance XALATAN</brief_summary>
	<brief_title>Effects Xal-Ease Patient Compliance With Xalatan</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>40 80 year old Diagnosis warranting treatment Xalatan eye drop . ambulatory well function nonambulatory le 40 great 80 year old Not use Xalatan eye drop</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>glaucoma</keyword>
	<keyword>compliance</keyword>
	<keyword>eye drop</keyword>
	<keyword>deliver aid</keyword>
	<keyword>Patients could range anywhere 40 80 year old</keyword>
	<keyword>Patients must diagnosis require treatment Xalatan .</keyword>
	<keyword>Patients male female racial/ethnic background .</keyword>
</DOC>